Show simple item record

dc.contributor.authorLi, Ken
dc.contributor.authorDjoukhadar, Ien
dc.contributor.authorZhu, Xen
dc.contributor.authorZhao, Sen
dc.contributor.authorLloyd, Sen
dc.contributor.authorMcCabe, Men
dc.contributor.authorMcBain, Catherine Aen
dc.contributor.authorEvans, Den
dc.contributor.authorJackson, Aen
dc.date.accessioned2015-09-24T09:09:16Zen
dc.date.available2015-09-24T09:09:16Zen
dc.date.issued2015-08-26en
dc.identifier.citationVascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. 2015: Neuro-oncologyen
dc.identifier.issn1523-5866en
dc.identifier.pmid26311690en
dc.identifier.doi10.1093/neuonc/nov168en
dc.identifier.urihttp://hdl.handle.net/10541/578677en
dc.description.abstractAntiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Neuro-oncologyen
dc.titleVascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.en
dc.typeArticleen
dc.contributor.departmentWolfson Molecular Imaging Centre, The University of Manchester, Manchester, UKen
dc.identifier.journalNeuro-oncologyen
html.description.abstractAntiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting.


This item appears in the following Collection(s)

Show simple item record